Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R44AI165188-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2024
  • Known Financial Commitments (USD)

    $300,000
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    THOMAS HUGHES
  • Research Location

    United States of America
  • Lead Research Institution

    MONTANA MOLECULAR, LLC
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SUMMARY STATEMENT The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be effectively treated. Montana Molecular makes and sells live cell, fluorescent biosensor assays for disease research and drug discovery. In response to the COVID-19 pandemic, Montana Molecular applied its expertise and background in live cell assay development to build fluorescent biosensors for the SARS-CoV-2 main protease, 3CLpro. The prototype sensor described in this proposal demonstrates feasibility. Direct to Phase II support is requested here to speed the development of even brighter, more sensitive assays for the 3CLpro and PLpro proteases. These assays can be used in high throughput screening for compounds that inhibit the protease, and engage with their target in living, human cells. 406-539-7399 366 Gallatin Park Drive Suite A Bozeman, MT 59715